Search results for "urologia"

showing 10 items of 1005 documents

Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

2022

Objective: This study was undertaken to describe and compare disease course and prognosis of early (ie, disease onset before age 11 years) and late (ie, disease onset after age 11 years) onset pediatric multiple sclerosis. Methods: Prospectively collected clinical information from Italian Multiple Sclerosis Register of 1993 pediatric multiple sclerosis patients, of whom 172 had early onset, was analyzed. Cox models adjusted for sex, baseline Expanded Disability Status Scale score, and disease-modifying treatments and stratified for diagnostic criteria adopted (Poser vs McDonald) were used to assess the risk of reaching irreversible Expanded Disability Status Scale scores of 3, 4, and 6, and…

MaleNatural History of Multiple SclerosisMultiple SclerosisNeurologyRecurrencePediatric Multiple SclerosisDisease ProgressionHumansDisabled PersonsSettore MED/26 - NeurologiaNeurology (clinical)ChildPrognosis
researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9…

2012

A large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72, a gene located on chromosome 9p21, has been recently reported to be responsible for 40% of familial amyotrophic lateral sclerosis cases of European ancestry. The aim of the current article was to describe the phenotype of amyotrophic lateral sclerosis cases carrying the expansion by providing a detailed clinical description of affected cases from representative multi-generational kindreds, and by analysing the age of onset, gender ratio and survival in a large cohort of patients with familial amyotrophic lateral sclerosis. We collected DNA and analysed phenotype data for 141 index Italian familial amyotrophic l…

MaleParentsPathologyphenotype-genotype correlationCohort Studies0302 clinical medicineC9orf72amyotrophic lateral sclerosigeneticsAmyotrophic lateral sclerosisAge of Onsetamyotrophic lateral sclerosis; familial als; C9Orf72; phenotype-genotype correlation0303 health sciencesSex CharacteristicsDNA Repeat ExpansionAdult Age of Onset Aged Amyotrophic Lateral Sclerosis; genetics/pathology Cohort Studies DNA Repeat Expansion DNA; genetics Female Humans Italy Male Middle Aged Mutation; genetics Parents Pedigree Phenotype Proteins; genetics Sex Characteristics Survival AnalysisMiddle Aged3. Good healthPedigreeSettore MED/26 - NEUROLOGIAPhenotypeItalyC9Orf72Settore MED/26 - NeurologiaFemaleFrontotemporal dementiaAdultmedicine.medical_specialtySOD1BiologyTARDBP03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyAgedamyotrophic lateral sclerosis familial ALS C9ORF72 gene phenotype–genotype correlationC9orf72 ProteinAmyotrophic Lateral Sclerosisgenetics/pathologyProteinsOriginal ArticlesDNAmedicine.diseaseSurvival AnalysisC9orf72 ProteinSettore BIO/18 - Geneticaamyotrophic lateral sclerosis; familial ALS C9ORF72 gene; phenotype-genotype correlation;MutationNeurology (clinical)Age of onsetTrinucleotide repeat expansionfamilial al030217 neurology & neurosurgery
researchProduct

Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease

2008

Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which results in a loss of kinase domain on the PINK1 protein (D297fsX318). This mutation was identified in two brothers with early-onset Parkinson disease (EOPD) from a Sicilian consanguineous family. Of note, while one of the two patients developed mental deterioration and psychiatric problems, the other showed no cognitive decline. The present study supports the view that PINK1 is a pathogenic gene in some Italian families with EOPD and contributes to define the PINK1-associated phenotype. Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which r…

MaleParkinson's diseaseGenotypeParkinson's diseaseMolecular Sequence DataPINK1DiseaseBiologyAntiparkinson AgentsLevodopaExonmedicineHumansAmino Acid SequenceAge of OnsetCognitive declineGeneAgedGeneticsGenotype–phenotype correlationPINK1Parkinson DiseaseExonsFamilial formmedicine.diseasePhenotypePedigreeSettore BIO/18 - GeneticaPhenotypeNeurologyMutationMutation (genetic algorithm)Settore MED/26 - NeurologiaNeurology (clinical)Geriatrics and GerontologyCognition DisordersProtein KinasesGene DeletionParkinsonism & Related Disorders
researchProduct

Preliminary experience with a transcranial magnetic resonance-guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series o…

2018

OBJECTIVETranscranial magnetic resonance–guided focused ultrasound surgery (tcMRgFUS) is one of the emerging noninvasive technologies for the treatment of neurological disorders such as essential tremor (ET), idiopathic asymmetrical tremor-dominant Parkinson’s disease (PD), and neuropathic pain. In this clinical series the authors present the preliminary results achieved with the world’s first tcMRgFUS system integrated with a 1.5-T MRI unit.METHODSThe authors describe the results of tcMRgFUS in a sample of patients with ET and with PD who underwent the procedure during the period from January 2015 to September 2017. A monolateral ventralis intermedius nucleus (VIM) thalamic ablation was pe…

MaleParkinson's diseaseMovement disordershigh-intensity focused ultrasound ablationIntraoperative Neurophysiological Monitoringmedicine.medical_treatmentinterventional030218 nuclear medicine & medical imagingMagnetic resonance guided focused ultrasound surgery0302 clinical medicineThalamusEssential tremorSettore MED/27 - NeurochirurgiaUltrasoundSettore MED/37 - NeuroradiologiaParkinson DiseaseGeneral MedicineMiddle AgedAblationMagnetic Resonance ImagingTreatment OutcomeNeuropathic painBBB = blood-brain barrier; ET = essential tremor; FRFSE = fast recalled FSE; FSE = fast spin echo; FSPGR = fast spoiled gradient echo; FTM = Fahn-Tolosa-Marin; HI-FU = high-intensity focused ultrasound; MRI; MRgFUS; MS = multiple sclerosis; PD = Parkinson’s disease; Parkinson’s disease; QUEST = Quality of Life in Essential Tremor; SWAN = susceptibility-weighted angiography; UPDRS = Unified Parkinson’s Disease Rating Scale; VIM = ventralis intermedius nucleus; brain; essential tremor; high-intensity focused ultrasound ablation; interventional; magnetic resonance–guided focused ultrasound surgery; stereotactic technique; tcMRgFUS = transcranial magnetic resonance–guided focused ultrasound surgerySettore MED/26 - NeurologiaFemaleRadiologymedicine.symptombrain; essential tremor; high-intensity focused ultrasound ablation; interventional; magnetic resonance-guided focused ultrasound surgery; mrgfus; mri; parkinson's disease; stereotactic techniqueMRIAdultmedicine.medical_specialtybrainEssential Tremormagnetic resonance–guided focused ultrasound surgery03 medical and health sciencesmedicineHumansmagnetic resonance-guided focused ultrasound surgeryUltrasonography InterventionalAgedThalamotomybusiness.industryMRgFUSmedicine.diseasestereotactic techniqueparkinson's diseaseParkinson’s diseaseSurgeryNeurology (clinical)businessSettore MED/36 - Diagnostica Per Immagini E Radioterapia030217 neurology & neurosurgeryFollow-Up StudiesNeurosurgical focus
researchProduct

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving…

2011

Abstract Background Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly. Methods In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and corre…

MalePathologyNeurologyDiseaseRelapsing-RemittingNeuropsychological Testslcsh:RC346-4290302 clinical medicineRelapsing-Remitting Multiple Sclerosi030212 general & internal medicine10. No inequalitymedicine.diagnostic_testBrainGeneral MedicineMagnetic Resonance Imaging3. Good healthFemaleSettore MED/26 - NeurologiaRadiologyNeurosurgeryMagnetic Resonance Imaging; Neuroimaging; Immunologic Factors; Dose-Response Relationship Drug; Humans; Brain; Interferon-beta; Quality of Life; Multiple Sclerosis Relapsing-Remitting; Cognition Disorders; Adult; Neuropsychological Tests; Female; MaleDrugInterferon beta-1aResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisClinical NeurologyNeuroimagingDose-Response Relationship03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingNeuroimagingmedicineImmunologic FactorsHumansNeurochemistrylcsh:Neurology. Diseases of the nervous systemDose-Response Relationship Drugbusiness.industryMultiple sclerosisMagnetic resonance imagingBrain Magnetic Resonance ImagingInterferon-betamedicine.diseaseClinical trialBrain Magnetic Resonance Imaging; Relapsing-Remitting Multiple Sclerosis; Interferon beta-1aQuality of LifeNeurology (clinical)businessCognition Disorders030217 neurology & neurosurgery
researchProduct

Lymphocytic Mitochondrial Aconitase Activity is Reduced in Alzheimer's Disease and Mild Cognitive Impairment

2015

Background: Specific mechanisms behind the role of oxidative/nitrosative stress and mitochondrial dysfunction in Alzheimer's disease (AD) pathogenesis remain elusive. Mitochondrial aconitase (ACO2) is a Krebs cycle enzyme sensitive to free radicalmediated damage. Objective: We assessed activity and expression of ACO2 extracted from blood lymphocytes of subjects with AD, mild cognitive impairment (MCI), older adults with normal cognition (OCN, age >= 65 years), and younger adults with normal cognition (YCN, age < 65 years). Plasma levels and activities of antioxidants were also measured. Methods: Blood samples were collected from 28 subjects with AD, 22 with MCI, 21 OCN, and 19 YCN. ACO2 act…

MalePathologyantioxidantAntioxidantmedicine.medical_treatmentLymphocyteMitochondrionmedicine.disease_causePolymerase Chain ReactionPathogenesisVitamin Eoxidative stressLymphocytesaconitase (aconitate hydratase)Aconitate Hydratasereactive oxygen speciesGeneral NeuroscienceACO2General MedicineAlzheimer's diseasemitochondriaPsychiatry and Mental healthClinical Psychologyantioxidantsmedicine.anatomical_structureDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer diseaseAlzheimer's diseaseAzheimer diseasereactive nitrogen speciemedicine.medical_specialtyaconitase (aconitate hydratase); Alzheimer disease; antioxidants; free radicals; lymphocyte; mild cognitive impairment; mitochondria; oxidative stress; reactive nitrogen species; reactive oxygen speciesBlotting Westernfree radicalslymphocytemild cognitive impairmentInternal medicinemedicineHumansCognitive DysfunctionRNA MessengerAgedfree radicaloxidative strebusiness.industryVitamin EAconitasimedicine.diseasereactive nitrogen speciesEndocrinologyGeriatrics and GerontologyAlzheimer's disease; Aconitasi; oxidative stress; Aconitase (aconitate hydratase) Azheimer disease antioxidants free radicals lymphocyte mild cognitive impairment mitochondria oxidative stress reactive nitrogen species reactive oxygen speciesMental Status SchedulebusinessBiomarkersOxidative stressJournal of Alzheimer's Disease
researchProduct

Progressive necrotic encephalopathy following tacrolimus therapy for liver transplantation.

2009

Previously described neurologic damage induced by immunosuppressive treatments includes transient or reversible central nervous system involvement. We describe a 57-year-old man who underwent liver transplantation and was started on immunosuppressive therapy with tacrolimus (FK506). Six months later, he started complaining of a progressive motor and sensory impairment of the left side, together with cognitive impairment. Brain MRI showed an enlarging lesion of the white matter with peripheral contrast enhancement. PET study indicated severe hypometabolism in the right hemisphere and spectroscopic MRI showed a peak of choline and relative reduction of other metabolites. Findings of CSF exami…

MalePathologymedicine.medical_specialtyNeurologyMagnetic Resonance Spectroscopymedicine.medical_treatmentEncephalopathyDermatologyBrain damageLiver transplantationTacrolimusWhite PeopleWhite matterLesionNecrosisProgressive necrotic encephalopathy liver transplantation.MedicineHumansHepatitis ChronicBrain Diseasesbusiness.industrySettore MED/27 - NeurochirurgiaBrainGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTacrolimusLiver TransplantationPsychiatry and Mental healthmedicine.anatomical_structurePositron-Emission TomographyDisease ProgressionSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerymedicine.symptombusinessImmunosuppressive AgentsFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Fate of autologous dermal stem cells transplanted into the spinal cord after traumatic injury (TSCI)

2003

Rat dermis is a source of cells capable of growing in vitro and, in appropriate conditions, forming floating spheres constituted by nestin-positive cells. We have clonally grown these spheres up to the 15th generation. These spheres can be dissociated into cells that differentiate in vitro under appropriate conditions, these cells are labeled by antibodies to immature neuron markers such as nestin and beta-tubulin III and, later, to mature neuron markers such as microtubule-associated protein 2 and neurofilaments. However, most cells are positive to the astroglial marker glia fibrillary acidic protein (GFAP). When sphere-derived cells are transplanted into the spinal cord after traumatic in…

MalePathologymedicine.medical_specialtyTime Factorstiming of transplantationNeurofilamentCellular differentiationBlotting Westernstem cell migrationPolymerase Chain ReactionRats Sprague-DawleyCell MovementGlial Fibrillary Acidic ProteinmedicineAnimalsstem cell differentiationSpinal Cord InjuriesNeuronsrecovery from disabilityGlial fibrillary acidic proteinbiologystem cell migration; stem cell differentiation; timing of transplantation; recovery from disabilityStem CellsGeneral NeuroscienceCell DifferentiationDermisRecovery of FunctionNestinRatsTransplantationmedicine.anatomical_structureImmunologySettore BIO/14 - Farmacologiabiology.proteinSettore MED/26 - NeurologiaNeuronAntibodyStem cellStem Cell TransplantationNeuroscience
researchProduct

Expression of vesicle-associated membrane-protein-associated protein B cleavage products in peripheral blood leukocytes and cerebrospinal fluid of pa…

2013

Background and purpose Vesicle-associated membrane-protein-associated protein B (VAPB) is an endoplasmic reticulum (ER) resident protein participating in ER function, vesicle trafficking, calcium homeostasis and lipid transport. Its N-terminal domain, named MSP, is cleaved and secreted, serving as an extracellular ligand. VAPB mutations are linked to autosomal-dominant motor neuron diseases, including amyotrophic lateral sclerosis (ALS) type 8. An altered VAPB function is also suspected in sporadic ALS (SALS). Methods The expression pattern of VAPB cleavage and secreted products in the peripheral blood leukocytes (PBL) and cerebrospinal fluid (CSF) of SALS patients and neurological controls…

MalePathologymedicine.medical_specialtyamyotrophic lateral sclerosisnematode major sperm proteinproteolysisVesicular Transport ProteinsStatistics Nonparametriccerebrospinal fluidCerebrospinal fluidparasitic diseasesLeukocytesmedicineHumansperipheral blood leukocytesSecretionAmyotrophic lateral sclerosisAgedbiologybusiness.industryEndoplasmic reticulumvesicle-associated membrane-protein-associated protein AMiddle AgedVAPBmedicine.diseaseMolecular biologyvesicle-associated membrane-protein-associated protein Bamyotrophic lateral sclerosis cerebrospinal fluid nematode major sperm protein peripheral blood leukocytes proteolysis vesicleassociated membraneprotein- associated protein A vesicleassociated membraneprotein- associated protein BMolecular WeightBlotSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaVesicle-associated membrane proteinNeurologyMutationbiology.proteinSettore MED/26 - NeurologiaFemaleNeurology (clinical)Antibodybusiness
researchProduct